Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york blog main
2
×
antisense oligonucleotide
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
benzodiazepines
biogen
blackstone group
blackstone life sciences
bluebird bio
columbia university
david goldstein
depression
duchenne muscular dystrophy
dyne therapeutics
epi4k
epilepsy
essential tremor
facioscapulohumeral muscular dystrophy
gene therapy
investing
joshua brumm
kaleido biosciences
kiran reddy
major depressive disorder
marcio souza
muscular dystrophy
myotonic dystrophy type 1
new york top stories
perimenopausal depression
praxis precision medicines
What
genetic
2
×
medicines
ago
aims
backed
biotechs
cause
ceo
considering
data
diseases
drug
drugs
dyne
early
epilepsy
expected
experimental
eyes
genes
having
humans
ipo
ipos
links
long
marcio
muscle
mutations
neuro
new
praxis
precision
rare
reach
research
souza
stop
therapeutics
turn
Language
unset
Current search:
boston
×
genetic
×
" new york blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs